Results 71 to 80 of about 19,858 (215)

The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review

ESC Heart Failure, Volume 12, Issue 2, Page 733-760, April 2025.
Abstract Implantable cardioverter defibrillators (ICDs) reliably prevent death due to life‐threatening arrhythmias; this may become less relevant in people with more severe heart failure who are reaching the end of life (EOL). This review aimed to explore the ICD deactivation process and identify ethical issues, especially around the initiation of ...
Siobhan C. Murray, Claire McNamara, Anna V. Chatzi   +2 more
wiley   +1 more source

Prognosis of Heart Failure with Stable Mid-Range Ejection Fraction in Comparison to Heart Failure with Stable Reduced Ejection Fraction and Heart Failure with Stable Preserved Ejection Fraction [PDF]

Journal of Cardiac Failure, 2019
Background Heart failure with mid-range ejection fraction (HFmrEF) of 40-49% is an under-recognized class of CHF. Prognosis of HFmrEF in comparison to HFrEF and HFpEF with stable EF of 1 year is unclear. Objectives We hypothesized that HFmrEF patients with stable EF of 1 year have different mortality and morbidity prognosis compared to HFrEF and ...
Mohamad Khaled Soufi, Mohamed Faher Almahmoud, Rishabh R. Jain, Joseph R. Mcfarland, Simon Pinsky, Milin N. Rana, Precious Ogbonna, Wissam I. Khalife   +7 more
openaire   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Approach to the Treatment of Heart Failure With Preserved Ejection Fraction and Mid- Range Ejection Fraction

International Cardiovascular Forum Journal, 2017
In this article we discuss the treatment of heart failure (HF) with preserved ejection fraction (HFpEF) and of HF with mid-range ejection fraction (HFmrEF) as has received considerable interest since the publciation of the 2016 European Society of Cardiology (ESC) heart failure guidelines. Since clinical trials on HFpEF have included also patients with
Ewa A Jankowska, Andrew JS Coats, Stefan D Anker   +2 more
openaire   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Heart failure with preserved, mid‐range, and reduced ejection fraction across health care settings: an observational study

ESC Heart Failure, 2022
Aims This study aimed to assess the sex‐specific distribution of heart failure (HF) with preserved, mid‐range, and reduced ejection fraction across three health care settings.
Annemarijn R. deBoer, Ilonca Vaartjes, Aisha Gohar, Mark J.M. Valk, Jasper J. Brugts, Leandra J.M. Boonman‐de Winter, Evelien E. vanRiet, Yvonne vanMourik, Hans‐Peter Brunner‐La Rocca, Gerard C.M. Linssen, Arno W. Hoes, Michiel L. Bots, Hester M. denRuijter, Frans H. Rutten   +13 more
doaj   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Heart Failure Mid-Range Ejection Fraction.

Arquivos brasileiros de cardiologia, 2021
Martinez, Paula Felippe, Okoshi, Marina Politi, Okoshi, Katashi, De Oliveira, Silvio Assis   +3 more
openaire   +3 more sources

P6330Obesity paradox in heart failure with mid-range ejection fraction

European Heart Journal, 2019
Abstract Background Obesity is identified as an independent risk factor for developing congestive heart failure (HF). Paradoxically it has been reported that obesity is associated with improved survival in different cohorts of HF patients.
E Zamora, J Lupon, M De Antonio, M Domingo, P Moliner, E Santiago-Vacas, J Santesmases, M Boldo, C Diez-Quevedo, M I Troya, C Rivas, B Gonzalez, V Diaz, P Velayos, A Bayes-Genis   +14 more
openaire   +1 more source